Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT: Correlation Between Functional Imaging and Histology

被引:14
|
作者
Vaz, Sofia [1 ]
Oliveira, Carla [1 ]
Castanheira, Joana C. [1 ]
Silva, Angelo F. [1 ]
Costa, Durval C. [1 ]
机构
[1] Champalimaud Fdn, Dept Nucl Med, Ave Brasilia, P-1400038 Lisbon, Portugal
关键词
PSMA PET; CT; prostate cancer; GIST; molecular imaging; PSMA specificity; PSMA expression; GASTROINTESTINAL STROMAL TUMOR; MEMBRANE ANTIGEN; EXPRESSION; PET/CT;
D O I
10.1097/RLU.0000000000002347
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Prostate-specific membrane antigen (PSMA) is specific for prostate cancer cells; nevertheless when finding uptake in abnormal locations for prostate cancer metastases, it is important to consider other hypothesis, including second cancers. There are several papers about PSMA expression in many different types of cancer, but few reported expression in gastrointestinal stromal tumors (GIST). In this case, we documented the GIST lesion not only by PET/CT but also by gastroscopy and histology. Additionally, PSMA immunochemistry was performed, showing PSMA expression in tumoral GIST cells (not in endothelial cells), evidencing a good correlation between PET/CT image and histology.
引用
收藏
页码:E488 / E491
页数:4
相关论文
共 50 条
  • [31] 68Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer
    Hruby, George
    Eade, Thomas
    Emmett, Louise
    Ho, Bao
    Hsiao, Ed
    Schembri, Geoff
    Guo, Linxin
    Kwong, Carolyn
    Hunter, Julia
    Byrne, Keelan
    Kneebone, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (04) : 343 - 346
  • [32] Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients
    Cem Onal
    Gokhan Ozyigit
    Ezgi Oymak
    Ozan Cem Guler
    Burak Tilki
    Pervin Hurmuz
    Fadil Akyol
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 3683 - 3692
  • [33] 99mTc-PSMA-SPECT/CT is a valuable alternative to 68Ga-PSMA-PET/CT in prostate cancer patients
    Liepe, K.
    Baehr, M.
    Hoang, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S217 - S217
  • [34] 68Ga-PSMA-PET/CT in newly diagnosed patients on active surveillance (PASPoRT study)
    Polm, P. D.
    Lavalaye, J.
    Soeterik, T. F. W.
    Stijns, P. E. F.
    Van Melick, H. H. E.
    Van den Bergh, R.
    EUROPEAN UROLOGY, 2021, 79 : S1277 - S1277
  • [35] Utility of 68Ga-PSMA-PET/CT in Prostate Cancer with Biochemical Recurrence with PSA≤1
    Geraldo, L.
    Uprimny, C.
    Kendler, D.
    Kroiss, A.
    Nilica, B.
    Scarpa, L.
    Decristoforo, C.
    Griesmacher, A.
    Lukas, P.
    Horninger, W.
    Virgolini, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S346 - S347
  • [36] 68Ga-PSMA-PET/CT as a changing practice tool in biochemically recurrent prostate cancer
    Domingues, P. M.
    Abreu, T.
    Siqueira, M. B.
    Marinho, G.
    Rosa, D.
    Cottas, H.
    Araujo, L. H.
    Herchenhorn, D.
    Peixoto, F. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] 68Ga-PSMA-PET imaging for detection of biochemical recurrences after definitive irradiation of the prostate
    Dewes, S.
    Schiller, K.
    Sauter, K.
    Eiber, M.
    Maurer, T.
    Schwaiger, M.
    Gschwend, J. E.
    Combs, S. E.
    Habl, G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 : 117 - 117
  • [38] The significance of nomograms for predicting node metastasis in 68ga-PSMA-PET/CT in prostate cancer
    Onal, C.
    Guler, O. C.
    Torun, N.
    Reyhan, M.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S623 - S623
  • [39] Radioiodine Uptake in Incidentally Detected Neuroendocrine Tumor Correlative Imaging With FDG PET/CT and 68Ga-DOTATATE PET/CT
    Hod, Nir
    Lantsberg, Sophie
    Levin, Daniel
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (10) : E643 - E646
  • [40] 68Ga-PSMA PET/CT Imaging in Multiple Myeloma
    Sasikumar, Arun
    Joy, Ajith
    Pillai, M. R. A.
    Nanabala, Raviteja
    Thomas, Boben
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (02) : E126 - E127